OKYO Projected Dividend Yield

Ord (New)/OKYO Pharma Ltd ( NASDAQ : OKYO )

OKYO Pharma is a preclinical biopharmaceutical company developing therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Co.'s research program is focused on a G Protein-Coupled Receptor. Co.'s preclinical product candidate, OK-101, is focused on keratoconjunctivitis sicca, commonly referred to as dry-eye disease (DED), which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. Co. has also been evaluating OK-201, a bovine adrenal medulla lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.

21 YEAR PERFORMANCE RESULTS